TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Opthea ( (AU:OPT) ) has shared an announcement.
Opthea Limited announced the resignation of four directors following the failure of its Phase 3 trials to meet primary endpoints and a significant workforce reduction. The company is in negotiations with Development Funding Agreement investors to explore future options, amidst trading suspensions on ASX and Nasdaq due to financial uncertainties.
The most recent analyst rating on (AU:OPT) stock is a Buy with a A$1.25 price target. To see the full list of analyst forecasts on Opthea stock, see the AU:OPT Stock Forecast page.
More about Opthea
Opthea Limited operates in the biotechnology industry, focusing on the development of therapies for treating eye diseases. The company is primarily engaged in advancing ophthalmology science through clinical trials and drug development.
YTD Price Performance: -25.93%
Average Trading Volume: 6,651,653
Technical Sentiment Signal: Sell
Current Market Cap: A$738.8M
Learn more about OPT stock on TipRanks’ Stock Analysis page.